We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Brain Tumor DNA Tracked Through the Bloodstream

By LabMedica International staff writers
Posted on 20 Apr 2011
Aberrant DNA can be tracked on an individual basis in the blood of patients suffering from primary aggressive brain tumors. More...


Following surgery to remove a tumor, the tissue can be sequenced and the blood taken at the same time can analyzed for the presence of the specific glioblastoma DNA.

Scientists at University of Cincinnati, (Cincinnati, OH, USA), working with a multidisciplinary team, have begun sequencing individual glioblastoma genomes and tracking abnormalities through the bloodstream. They hope that by mapping the various DNA rearrangements of glioblastoma tumors they will be able to establish biomarkers that will help them track the cancer's progress and guide their efforts to treat patients more effectively. They also hope the biomarkers will help them identify targets for new, improved therapies for the future.

The sequencing of glioblastoma multiforme (GBM) tumors will be done on the GenomeAnalyzer (Illumina Inc., San Diego, CA, USA), and performed by the department of genetics at Albert Einstein College of Medicine (New York, NY, USA). Equally important, the discovery of biomarkers may provide scientists with new therapeutic targets. By identifying a specific genetic abnormality or mutation, for example, they can work to develop a future therapy that attacks that mutation.

Olivier Rixe, MD, PhD, the study's principal investigator, said, "There will be some circulating DNA in the blood coming from the tumor, and we will follow those very specific abnormalities. It is very much a personalized study, because we are not talking about the genetic abnormalities of other patients. We are talking about the sequencing of a biopsy of a specific individual's tumor. And we are talking about tracking individualized, personalized abnormalities.”

Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain tumor in humans, involving glial cells and accounting for 52% of all parenchymal brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2-3 cases per 100,000 people in Europe and North America.

Related Links:

University of Cincinnati
Illumina Inc.
Albert Einstein College of Medicine



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Motorized Pipette
PIPETMAN M96
New
Automated IFA Analyzer
HELIOS HTC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.